Precursor Igf-ii (Proigf-ii) And Mature Igf-ii (Migf-ii) Induce Bcl-2 And Bcl-x_l Expression Through Different Signaling Pathways In Breast Cancer Cells

References

• Benz CC. HER2 and endocrine response in breast cancer: the evidence for clinical application of estrogen receptor status. Oncol Exchange 2004; 3(21)8–11
   Google Scholar
• Catz SD, Johnson JL. Transcriptional regulation of Bcl-2 by NF-KB and its significance in prostate cancer. Oncogene 2001; 20(50)7342–7351
   PubMedGoogle Scholar
• Dearth RK, Cui X, Kim H-J, Hadsell DL, Lee AV. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007; 6(6)705–713
   PubMed Web of Science ®Google Scholar
• De León DD, Wilson DM, Powers M, Rosenfeld RG. Effects of IGFs and IGF receptor antibodies on the proliferation of breast cancer cells. Growth Factors 1992; 6(4)327–336
   PubMedGoogle Scholar
• España L, Martín B, Aragués R, Chiva C, Oliva B, Andreu D, Sierra A. Bcl-XL-mediated changes in metabolic pathways of breast cancer cells: From survival in the blood stream to organ-specific metastasis. Am J Pathol 2005; 167(4)1125–1137
   PubMedGoogle Scholar
• Fiebig AA, Zhu W, Hollerbach C, Leber B, Andrews DW. Bcl-XL is qualitatively different and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 2006; 6(213)
   PubMedGoogle Scholar
• Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007; 6(6)631–637
   PubMed Web of Science ®Google Scholar
• González-García M, Pérez-Ballestero R, Ding L, Duan L, Boise LH, Thompson CB, Nuñez G. Bcl-XL is the major Bcl-X mRNA form expressed during murine development and its product localizes to mitochondria. Development 1994; 120: 3033–3042
   PubMedGoogle Scholar
• Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, Klein HH, Lundemose AG. Sustained signaling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315: 271–279
   PubMed Web of Science ®Google Scholar
• Heffelfinger SC, Miller MA, Yassin R, Gear R. Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res 1999; 5: 2867–2876
   PubMed Web of Science ®Google Scholar
• Hers I, Bell CJ, Poole AW, Jiang D, Denton RM, Schaefer E. Reciprocal feedback regulation of insulin receptor and insulin substrate tyrosine phosphorylation by PI3K in primary adipocytes. Biochem J 2002; 368: 875–884
   PubMedGoogle Scholar
• Hirano S, Furutama D, Hanafusa T. Physiologically high concentrations of 17-B estradiol enhance NF-KB activity in human T cells. Am J Physiol Regul Integr Comp Physiol 2006; 292: 465–471
   Google Scholar
• Kalla Singh S, Moretta D, Almaguel F, Wall NR, De Léon M, De Léon D. Differential effect of proIGF-II and mIGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 2008; 25(6)363–372
   Google Scholar
• Kim EJ, Holthuizen PE, Kim J, Park JH. Overexpression of mature IGF-II leads to growth arrest in Caco-2 human colon cancer cells. Growth Horm IGF Res 2005; 15(1)64–71
   PubMedGoogle Scholar
• Korn E, Van Hoff J, Buckley P, Daughaday WH, Carpenter TO. Secretion of a large molecular-weight form of insulin-like growth factor by a primary renal tumor. Med Pediatr Oncol 1995; 24(6)392–396
   PubMedGoogle Scholar
• Lee AV, Darbre P, King RJ. Processing of IGF-II by human breast cancer cells. Mol Cell Endocrinol 1994; 99(2)211–220
   PubMedGoogle Scholar
• Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-KB mediated up-regulation of Bcl-X and Bfl-1/A1 is required for CD40survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96(16)9136–9141
   PubMedGoogle Scholar
• Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen KJ. Apoptosis suppressing protein Bcl-2 is expressed in well differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49–55
   PubMed Web of Science ®Google Scholar
• Liu W, Liu Y, Lowe WL. The role of PI3K and MAPK in IGF-I mediated effects in vascular endothelial cells. Endocrinology 2001; 142(5)1710–1719
   PubMedGoogle Scholar
• Méndez O, Martín B, Sanz R, Aragüés R, Moreno V, Oliva B, Stresing V, Sierra A. Underexpression of transcriptional regulators is common in metastatic breast cancer cells overexpressing Bcl-XL. Carcinogenesis 2006; 27(6)1169–1179
   PubMedGoogle Scholar
• Myers MG, Mendez R, Shi P, Pierce JH, Rhoads R, White MF. The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulates insulin signaling. J Biol Chem 1998; 273(41)26908–26914
   PubMedGoogle Scholar
• Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM. Overexpression of Bcl-X protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997; 3(4)230–237
   PubMedGoogle Scholar
• Rossé T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998; 391: 496–499
   PubMed Web of Science ®Google Scholar
• Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 2002; 21(54)8240–8250
   PubMed Web of Science ®Google Scholar
• Shaywitz AJ, Greenberg ME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999; 68: 821–861
   PubMed Web of Science ®Google Scholar
• Tsuruta F, Masuyama N, Gotoh Y. The PI3K-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002; 277(16)14040–14047
   PubMedGoogle Scholar
• Vyas S, Asmerom Y, DeLeon DD. Resveratrol regulates IGF-II in breast cancer cells. Endocrinology 2005; 146(10)4224–4233
   PubMed Web of Science ®Google Scholar
• Yang CQ, Zhan X, Hu X, Kondepudi A, Perdue JF. The expression and characterization of recombinant proIGF-IIand a mutant that is defective in the O-glycosylation of its E-domain. Endocrinology 1996; 137(7)2766–2773
   PubMedGoogle Scholar
• Yee D, Lee AV. Crosstalk between the IGFs and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5: 107–115
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt. Science 1999; 286: 1741–1744
   PubMed Web of Science ®Google Scholar
• Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NF-KB and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12: S37–S46
   PubMedGoogle Scholar